Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 4/20 | 0.53 |
| ▸ | CA1 | P00915 | 4/20 | 0.53 |
| ▸ | CA2 | P00918 | 4/20 | 0.53 |
| ▸ | CA4 | P22748 | 4/20 | 0.53 |
| ▸ | CA9 | Q16790 | 4/20 | 0.53 |
| ▸ | MAPT | P10636 | 5/20 | 0.51 |
| ▸ | PTGS2 | P35354 | 5/20 | 0.51 |
| ▸ | PTGS1 | P23219 | 3/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.51 |
| ▸ | LMNA | P02545 | 3/20 | 0.51 |
| ▸ | CXCR1 | P25024 | 2/20 | 0.51 |
| ▸ | CXCR2 | P25025 | 2/20 | 0.51 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.51 |
| ▸ | RECQL | P46063 | 1/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.51 |
| ▸ | HPGD | P15428 | 1/20 | 0.51 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.51 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.51 |
| ▸ | SLC22A6 | Q4U2R8 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1883564 | 0.79 | MAPT (0.64) | CA12CA1CA2CA4CA9 | |
| SCHEMBL1883565 | 0.79 | MAPT (0.64) | CA12CA1CA2CA4CA9 | |
| SCHEMBL6286873 | 0.77 | HTT (0.63) | CA12CA1CA2CA4CA9 | |
| SCHEMBL15486527 | 0.77 | MAPT (0.61) | CA12CA1CA2CA4CA9 | |
| SCHEMBL17286575 | 0.76 | ALDH1A1 (0.54) | MAPTPTGS2PTGS1ALDH1A1CYP3A4 | |
| SCHEMBL7011096 | 0.76 | CA12 (0.61) | CA12CA1CA2CA4CA9 | |
| SCHEMBL11707059 | 0.75 | PTGS1 (0.70) | MAPTPTGS2PTGS1ALDH1A1SMN1; SMN2 | |
| SCHEMBL11707068 | 0.75 | PTGS1 (0.70) | MAPTPTGS2PTGS1ALDH1A1SMN1; SMN2 | |
| SCHEMBL6319806 | 0.75 | MAPT (0.58) | CA12CA1CA2CA4CA9 | |
| SCHEMBL6277561 | 0.75 | MAPT (0.58) | CA12CA1CA2CA4CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-100368394-C | N- (2-aryl-propionyl) -sulfonamides and pharmaceutical compositions containing them | DOMPE SPA (IT) | 2008-02-13 | — | — | CN | disclosed |
| US-6887903-B1 | N-(2-aryl-propionyl)-sulfonamides and pharmaceutical preparations containing them | DOMPE S.P.A. (IT) | 2005-05-03 | — | — | US | disclosed |
| US-6881755-B2 | N-(2-aryl-propionyl)-sulfonamides and pharmaceutical preparations containing them | Dompé S.p.A. (IT) | 2005-04-19 | — | — | US | disclosed |
| US-20030216392-A1 | N - ( 2 - aryl - propionyl ) - sulfonamides and pharmaceutical preparations containing them | DOMPE S.P.A. | 2003-11-20 | — | — | US | disclosed |
| EP-1123276-B1 | N-(2-ARYL-PROPIONYL)-SULFONAMIDES AND PHARMACEUTICAL PREPARATIONS CONTAINING THEM | DOMPE SPA (IT) | 2003-01-08 | — | — | EP | disclosed |
| CN-1324344-A | N- (2-aryl-propionyl) -sulfonamides and pharmaceutical compositions containing them | DOMPE SPA (IT) | 2001-11-28 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030216392-A1 | N - ( 2 - aryl - propionyl ) - sulfonamides and pharmaceutical preparations containing them | ELANE, MPO, FPR1 | CA12 3761/4885CA1 3899/4885CA2 2887/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.